Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Ruoshuang HanHaoyue GuoJinpeng ShiSha ZhaoYijun JiaXiaozhen LiuYiwei LiuLei ChengChao ZhaoXuefei LiCaicun ZhouPublished in: BMC medicine (2024)